Abstract. Triple negative breast cancer (TNBC) has a poor outcome due to the lack of beneficial therapeutic targets. To clarify the molecular mechanisms involved in the carcinogenesis of TNBC and to identify target molecules for novel anticancer drugs, we analyzed the gene expression profiles of 30 TNBCs as well as 13 normal epithelial ductal cells that were purified by laser-microbeam microdissection. We identified 301 and 321 transcripts that were significantly upregulated and downregulated in TNBC, respectively. In particular, gene expression profile analyses of normal human vital organs allowed us to identify 104 cancer-specific genes, including those involved in breast carcinogenesis such as NEK2, PBK and MELK. Moreover, gene annotation enrichment analysis revealed prominent gene subsets involved in the cell cycle, especially mitosis. Therefore, we focused on cell cycle regulators, asp (abnormal spindle) homolog, microcephaly-associated (Drosophila) (ASPM) and centromere protein K (CENPK) as novel therapeutic targets for TNBC. Small-interfering RNA-mediated knockdown of their expression significantly attenuated TNBC cell viability due to G1 and G2/M cell cycle arrest. Our data will provide a better understanding of the carcinogenesis of TNBC and could contribute to the development of molecular targets as a treatment for TNBC patients.
Introduction
Breast cancer is one of the most common solid malignant tumors among women worldwide. Breast cancer is a heterogeneous disease that is currently classified based on the expression of estrogen receptor (ER), progesterone receptor (PgR), and the human epidermal growth factor receptor 2 (HER2) (1, 2) . For patients with ER-or PgR-positive breast cancer, approximately five years of adjuvant endocrine therapy reduces the annual breast cancer death rate by approximately 30% (3) . The addition of HER2-antagonist trastuzumab to adjuvant chemotherapy has improved the prognosis of HER2-positive breast cancer patients (4) (5) (6) . In contrast, triple negative breast cancer (TNBC), defined as tumors that are negative for ER, PgR and HER2 overexpression, accounts for at least 15-20% of all breast cancers, and the prognosis for TNBC patients is poor because of its propensity for recurrence and metastasis and a lack of clinically-established targeted therapies (7, 8) . Therefore, only neoadjuvant chemotherapy with conventional cytotoxic agents yield an excellent outcome for TNBC patients who have a complete pathological response, but the outcome for the vast majority with residual disease after chemotherapy is relatively poor compared to non-TNBC patients (6, 7) . Thus, because the heterogeneity of breast cancer makes it difficult to treat many subtypes, including TNBC, the molecular mechanisms of the carcinogenesis of TNBC must be elucidated to develop novel molecular-targeted therapies that improve the clinical outcome of TNBC patients.
Current 'omics' technology including DNA microarray analysis can provide very helpful information that can be used to categorize the characteristics of various malignant tumors and identify genes that may be applicable for the develop- ment of novel molecular targets for therapeutic modalities (9) . To this end, we analyzed the gene expression profile of 30 TNBC cells and normal breast ductal cells that were purified by laser-microbeam microdissection and identified a number of cancer-specific genes that might contribute to the carcino genesis of TNBC. TNBC gene expression profiling analysis can provide comprehensive information on the molecular mechanism underlying the carcinogenesis of TNBC and possibly lead to the development of novel effective therapies.
Materials and methods

Clinical samples and cell lines.
A total of 48 TNBC (18 cases did not entry DNA microarray analysis) and 13 normal mammary tissues were obtained with informed consent from patients who were treated at Tokushima Breast Care Clinic, Tokushima, Japan. This study, as well as the use of all clinical materials described above, was approved by the Ethics Committee of The University of Tokushima. Clinical information was obtained from medical records and tumors were diagnosed as triple-negative by pathologists when immunohistochemical staining was ER-negative, PR-negative, and HER2 (0 or 1+). The clinicopathological features of each patient are summarized in Table Ⅰ . Samples were immediately embedded in TissueTek OCT compound (Sakura, Tokyo, Japan), frozen, and stored at -80˚C. Human TNBC cell lines MDA-MB-231, BT-20, BT-549, HCC1143, and HCC1937 were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). The human normal breast epithelial cell line, MCF10A, was purchased from Cambrex Bioscience, Inc. All cells were cultured under the conditions recommended by their respective depositors.
Laser-microbeam microdissection (LMM)
, RNA extraction, RNA amplification, and hybridization. Frozen specimens were serially sectioned in 8-µm slices with a cryostat (Leica, Herborn, Germany) and stained with hematoxylin and eosin to define the analyzed regions. We purified 48 TNBC and 13 normal ductal cells using the LMM system (Carl Zeiss, Jena, Germany) according to the manufacturer's instructions. Dissected cancer and normal ductal cells were dissolved in RLT lysis buffer (Qiagen, Valencia, CA, USA) containing 1% β-mercaptoethanol. The extracted total RNA was purified with an RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. For RNA amplification and labeling, we used an Agilent Low-Input QuickAmp labeling kit according to the manufacturer's instructions. Briefly, 100 ng of total RNA from each sample was amplified using T7 RNA polymerase with simultaneous Cy3-labeled CTP incorporation. Then, 2 µg of Cy3-labeled cRNA was fragmented, hybridized onto the Agilent Whole Human Genome Microarray 4x44K slide (Agilent Technologies, Palo Alto, CA, USA) and then incubated with rotation at 65˚C for 18 h. Then slides were washed and scanned by the Agilent Microarray scanner system in an ozone protection fume hood.
Microarray analysis. The features of scanned image files containing the Cy3-fluorescence signals of the hybridized Agilent Microarrays were extracted using the Agilent Feature Extraction (version 9.5) (Agilent Technologies). The data were analyzed using GeneSpring (version 11.5). We normalized the microarray data across all chips and genes by quantile normalization, and baseline transformed the signal values to the median in all samples. Finally, we performed quality control and filtering steps based on flags and expression levels.
To identify genes that were significantly alternated between TNBC and normal ductal cells the mean signal intensity values in each analysis were compared. In this experiment, we applied Mann-Whitney (unpaired) t-test and random permutation test 10,000 times for each comparison and adjusted for multiple comparisons using the Benjamini Hochberg false discovery rate (FDR). Gene expression levels were considered significantly different when the FDR (corrected P-value) <5x10 -4 (when comparing normal ductal cells and TNBC) and the fold change was ≥5.0. Data from this microarray analysis has been submitted to the NCBI Gene Expression Omnibus (GEO) archive as series GSE38959.
Functional gene annotation clustering. The Database for Annotation, Visualization and Integrated Discovery (DAVID 6.7) was approved to detect functional gene annotation clusters based on gene expression profiling by gene annotation enrichment analysis (http://david.abcc.ncifcrf.gov/) (10, 11) . The clusters from the gene annotation enrichment analysis were selected in this study based on a previous report (12) .
Quantitative reverse transcription-PCR (qRT-PCR) analysis.
Total RNA was extracted from each TNBC cell line and clinical sample using an RNeasy mini kit (Qiagen) according to the manufacturer's instructions. Purified RNA from each clinical sample and cell line, as well as poly-A RNA from normal human heart, lung, liver, and kidney (Takara, Otsu, Japan) was reverse transcribed for single-stranded cDNA using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers with Superscript II reverse transcriptase (Invitrogen, Life Technologies, Carlsbad, CA, USA). qRT-PCR analysis was performed using an ABI PRISM 7500 Real-Time PCR system (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) and SYBR Premix Ex Taq (Takara) according to the manufacturer's instructions. The PCR primer sequences were as follows: 5'-GCAGGTCTCC TTTCCTTTGCT-3' and 5'-CTCGGCCTTCTTTGAGT GGT-3' for ASPM; 5'-CACTCACCGATTCAAATG CTC-3' and 5'-ACCACCGTTGTTCCCTTTCT-3' for CENPK; 5'-AAC TTAGAGGTGGGGAGCAG-3' and 5'-CACAACCATGCC TTACTTTATC-3' for β2 microglobulin (β2-MG) as a quantitative control.
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of each siRNA using Lipofectamine RNAiMAX Reagent (Invitrogen). To evaluate the gene-silencing effects of the siRNAs by qRT-PCR, total RNA was extracted from the siRNA-transfected cells as described above after the indicated times. The following specific qRT-PCR primer sets were used: 5'-CGGAAAAGAAAGAGCGATGG-3' and 5'-ACCACCAAGTGAAGCCCTGT-3' for ASPM and 5'-GG GTGCCATCATTTTCTGGT-3' and 5'-CCACCGTTGTT CCCTTTCTAAG-3' for CENPK. To evaluate cell viability, the MTT assay was performed using the cell counting kit-8 reagent (Dojindo, Kumamoto, Japan) according to the manufacturer's instructions. Absorbance at 450 nm was measured with a micro-plate reader infinite 200 (Tecan, Männedorf, Switzerland). These experiments were performed in triplicate.
Colony formation assay. Vector-based shRNAs and the psiU6BX3 expression system were constructed as previously described (13) . The shRNA target sequences were the same as those of the siRNA oligonucleotides. The DNA sequences of all constructs were confirmed by DNA sequencing. BT-20 and MDA-MB-231 cells were plated in 10-cm dishes (1x10 6 cells/dish) and transfected with 6 µg of psiU6BX3.0-ASPM or psiU6BX3.0-CENPK and psiU6BX3.0-EGFP as a control using Fugene-6 (Roche, Basel, Switzerland) according to the manufacturer's instructions. Forty-eight hours after transfection, cells were re-seeded for a colony formation assay (5.0x10 5 cells/10-cm dish) and RT-PCR (5.0x10 5 cells/10-cm dish). We selected psiU6BX3.0-transfected cells using selection medium containing 0.6 mg/ml of neomycin for BT-20 cells and 1.4 mg/ml for MDA-MB-231 cells. Total RNA was extracted from the cells after a 7-day incubation with neomycin, and then the knockdown effects of the siRNAs were examined by qRT-PCR. The specific primer sets for quantitative RT-PCR were the same as those for the siRNA oligonucleotides. Nineteen days after transfection, the cells were fixed with 4% paraformaldehyde for 10 min and stained with Giemsa solution (Merck, Darmstadt, Germany).
Cell cycle analysis. For flow cytometric analysis, adherent and detached cells were harvested and fixed with 70% ethanol at room temperature for 30 min. After washing with PBS (-), the cells were incubated at 37˚C for 30 min with 1 mg/ml RNase Ⅰ in PBS (-) and stained with 20 µg propidium iodide at room temperature for 30 min in the dark. A total of 10,000 cells were analyzed for DNA content using flow cytometry and CellQuest software (FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA). Assays were performed in duplicate.
Immunocytochemical staining analysis. HCC1937 and MDA-MB-231 cells were plated onto a 2-well glass slide (Thermo Fisher Scientific, Rochester, NY, USA) at a density of 1.0x10 4 /well and incubated for 24 h before siRNA trans fection. Forty-eight hours post-transfection, the cells were fixed with 4% paraformaldehyde for 30 min at 4˚C and then permeablized with 0.1% Triton X-100 for 2 min at room temperature. Subsequently, the cells were covered with 3% bovine serum albumin for 60 min at room temperature and then incubated with an anti-α/β tubulin antibody (Cell Signaling, Beverly, MA, USA) diluted 1:50 for 1 h. After washing with PBS (-), the cells were stained with an Alexa 488-conjugated antirabbit secondary antibody (Molecular Probes, Eugene, OR, USA) diluted 1:1,000 for 1 h. The nuclei were counterstained with 4' ,6'-diamidine-2'-phenylindole dihydrochloride (DAPI). Fluorescent images were obtained using an IX71 microscope (Olympus, Tokyo, Japan). 
Results
Identification of genes upregulated or downregulated in
TNBCs. To obtain precise expression profiles of TNBC cells, we used LMM to avoid contamination of non-cancer cells, such as adipocytes, fibroblasts, and inflammatory cells from the tissue sections (Fig. 1A, upper panels) . Because breast cancer originates from normal breast ductal cells, we used similarly purified populations of normal duct cells as controls (Fig. 1A , lower panels). The precise gene-expression profiles of TNBC by DNA microarray identified 301 genes that were upregulated >5-fold in TNBC compared to 13 normal ductal cells, and 321 genes that were downregulated to <1/5 of the normal ductal cells (Fig. 1B) . Table Ⅱ lists the 301 upregulated genes in TNBC, including ubiquitin-conjugating enzyme E2C (UBE2C) (14) , S100 calcium binding protein P (S100P) (15) , ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) (UCHL1) (16) , pituitary tumor-transforming 1 (PTTG1) (17) , ubiquitinconjugating enzyme E2T (UBE2T) (13) , ubiquitin-like with PHD and ring finger domains 1 (UHRF1) (18) , SIX homeobox 1 (SIX1) (19) , and protein regulator of cytokinesis 1 (PRC1) (20) , which were previously reported to be overexpressed in breast cancer and involved in mammary carcinogenesis. In particular, topoisomerase (DNA) Ⅱα (TOP2A) (21, 22) , HORMA domain containing 1 (HORMAD1) (23) , ATPase family, Fatty acid binding protein 5 (psoriasis-associated) (FABP5) (24) , and AAA domain containing 2 (ATAD2) (25) were previously reported to be potentially involved in the carcinogenesis of TNBC, and to serve as prognostic markers or therapeutic targets for TNBC.
On the other hand, Table Ⅲ lists the 321 genes that were downregulated to <1/5 of normal ductal cells. Among these significantly downregulated genes, prolactin-induced protein (PIP) and dynein, axonemal, light intermediate chain 1 (DNALI1) were previously shown to be downregulated in TNBC (26) . In particular, suppression of WNT inhibitory factor 1 (WIF1) (27) and signal peptide, CUB domain, EGF-like (SCUBE2) (28) , both of which function as tumor suppressors, were among the genes that were downregulated as malignancy progressed. These data suggest that silencing or depletion of these genes might lead to the carcinogenesis of TNBC.
Identification of cancer-specific genes. Next, to develop novel therapeutic targets for TNBC with a minimum risk of adverse events, we performed a DNA microarray analysis of normal human vital organs consisting of the heart, lung, liver and kidney as well as TNBC cases and attempted to identify genes whose expression was exclusively upregulated in TNBC, but not expressed in normal vital organs. We identified 104 genes, which were specifically upregulated in TNBC, including cancer-specific molecules such as NIMA-related kinase 2 (NEK2) (29, 30) , PDZ binding kinase (PBK) (31) , denticleless homolog (Drosohila) (DTL) (32) , maternal leucine zipper kinase (MELK) (33) , and kinesin family member C (KIF2C) (34) , which have previously been shown to be involved in breast carcinogenesis (Fig. 1C and Table Ⅳ) .
Functional gene annotation clustering analysis. To elucidate the biological processes and pathways characterized in TNBC, we performed a functional analysis of these upregulated or downregulated genes in 30 TNBC cases using the gene annotation clustering of the DAVID algorithm. We identified the most prominent cluster (cluster 1; gene enrichment score, 29.90) composed of various functional annotation terms consisting of 87 upregulated genes in TNBC (Table Ⅴ) . Cluster 1 consisted almost entirely of cell cycle-associated genes as represented by nuclear division (fold enrichment, 15.04), mitosis (fold enrichment, 15.04), M phase of the mitotic cell cycle (fold enrichment, 14.78), organelle fission (fold enrichment, 14.45), and M phase (fold enrichment, 12.90) (Fig. 2) . These findings suggest that most of the upregulated genes in TNBC might be functionally responsible for cell cycle progression.
On the other hand, we also identified the most prominent cluster functionally deactivated in TNBC based on down- regulated genes in TNBC (cluster 2; enrichment score, 6.43).
As shown in Table Ⅴ and Fig. 2 , cluster 2 consisted of functions induced by extracellular matrix-cell adhesion-associated genes such as latent transforming growth factor β binding protein 2 (LTBP2), laminin α3 (LAMA3) and cell adhesion molecule with homology to L1CAM (close homolog of L1) (CHL1), which have been reported to be downregulated in various tumors (35) (36) (37) . These results suggest that loss of cell -cell or matrix-cell interactions might be a key mechanism in TNBC progression.
Identification of ASPM and CENPK as novel molecular targets for TNBC therapy. Because the upregulated genes were mainly included in the cell cycle-associated gene cluster as described above, we directed our focus to two cancer-specific genes that function as cell cycle regulators, asp (abnormal spindle) homolog, microcephaly associated (Drosophila) (ASPM), which is fundamental for cytokinesis (38) and centromere protein K (CENPK), which is essential for proper kinetochore assembly during mitosis (39), as novel therapeutic targets for TNBC. qRT-PCR experiments confirmed that ASPM and CENPK genes were significantly upregulated in 48 clinical TNBC cases (Fig. 3A) and five cell lines derived from TNBC (Fig. 3B ), but undetectably expressed in a mixture of 13 microdissected normal mammary ductal cells and the normal mammary epithelial cell line MCF10A as well as normal human vital organs.
To ascertain the possible roles of ASPM and CENPK in TNBC cell growth, we knocked down the expression of endogenous ASPM and CENPK in three TNBC cell lines, HCC1937, BT-20 and MDA-MB-231 cells, which highly express both of these genes (Fig. 3) , using RNAi. qRT-PCR experiments showed that ASPM and CENPK were significantly knocked down in cells transfected with siASPM and siCENPK, but not with siEGFP as a control (Fig. 4A) . In concordance with their knockdown, the MTT assay clearly revealed growth suppression of breast cancer cells in a time-dependent manner by siASPM and siCENPK, compared with a control siEGFP, which showed no knockdown (Fig. 4B) . In addition, a colony formation assay also confirmed that introducing both shRNA-ASPM and -CENPK constructs remarkably suppressed the growth of BT-20 and MDA-MB-231 cells, respectively, compared with shEGFP-transfected cells (Fig. 4C) , suggesting that both genes are likely indispensable for breast cancer cell growth. Furthermore, we investigated the phenotypic alterations of TNBC cells transfected with ASPM and CENPK siRNAs N/A, not annotated; P-value, Benjamini-Hochberg false discovery rate of random permutation test; log fold change, between groups. Gene symbol, accession number and gene name were exported from GeneSpring (from the NCBI databases). (Fig. 5B) . Interestingly, we observed an enlarged size of HCC1937 cells, which was likely due to abnormal tubulin formation due to decreased ASPM expression (Fig. 5C , arrowheads). In addition, we observed a disruption in the structural integrity of tubulin in CENPK-depleted MDA-MB-231 cells (Fig. 5D, arrowheads) , compared with those in siEGFPtransfected cells. These results suggest that the absence of ASPM and CENPK caused an arrest in the G2/M and G0/G1 phases, respectively, and then induced cell death. Taken together, these findings strongly suggest that ASPM and CENPK have indispensable roles in cell proliferation and mitosis, especially in the G2/M and G0/G1 phases, in TNBC cells.
Discussion
TNBC patients do not benefit from endocrine therapy and trastuzumab. Conventional chemotherapy is currently the mainstay of systemic medical treatment, although TNBC patients have a worse outcome after chemotherapy than patients with other breast subtypes. In particular, because cytotoxic drugs often cause severe adverse effects, it is obvious that thoughtful selection of novel target molecules based on the detailed molecular mechanisms of TNBC carcinogenesis Genes enriched in cluster 1 and cluster 2 according to DAVID. heart, lung, liver and kidney and identified 104 genes that were significantly upregulated in TNBC compared to normal duct cells, but not expressed in normal human vital organs. They included cancer specific kinases, such as NEK2, PBK, and MELK, which might serve as druggable targets for new therapeutic agents against TNBC.
NEK2, a member of the NIMA-related serine/threonine kinase family, is involved in cell division and the mitotic regulation by centrosome splitting, and is upregulated in a wide variety of human cancers including breast cancer (40) . siRNA-mediated depletion of NEK2 expression results in growth suppression of breast and colorectal cancers (29, 30) . PBK, a mitotic serine/ threonine kinase, is significantly upregulated in the majority of breast cancers. siRNA-mediated knockdown of PBK expression also results in significant suppression of cell growth due to cytokinetic failure (31) . MELK, a member of the snf1/AMPK serine-threonine kinase family, is involved in mammalian embryonic development and is also frequently upregulated in breast cancers and brain tumors (33, 41) . Suppression of MELK expression by siRNA significantly inhibits the growth of human breast cancer cells (33) . These findings strongly suggest that these cancer-specific kinases, NEK2, PBK and MELK, are promising therapeutic targets for TNBC.
Furthermore, we performed a gene-annotation enrichment analysis using DAVID based on gene expression profiling to elucidate the biological processes and pathways associated with each gene cluster. We found that the vast majority of genes upregulated in TNBC are functionally responsible for cell cycle progression involved in nuclear division, microtubule organization, kinetochore, and chromosome segregation, and that most inactivated functions closely related to TNBC progression are involved in cell-cell or cell-matrix interactions, which is consistent with epithelial mesenchymal transition (EMT) features as a phenotype of TNBC (42) .
To further the development of novel anticancer drugs with minimum adverse effects, we focused on the cancerspecific cell-cycle associated genes ASPM and CEPNK as novel molecular targets for TNBC therapy. ASPM has been reported to play an essential role in nucleating microtubules at centrosomes, to localize to the spindle poles during mitosis (39) and to contribute to glioblastoma cell growth (43), but has not been associated with breast carcinogenesis, especially TNBC. Here, we confirmed that ASPM is upregulated in clinical samples and TNBC cell lines (Fig. 3) and that siRNAmediated knockdown of endogenous ASPM results in the loss of nucleating microtubules through mitosis by impeding centrosome function, resulting in G2/M cell cycle arrest and subsequent apoptosis. These results suggest that aberrant ASPM expression might be involved in the carcinogenesis of TNBC and that ASPM targeting might be an attractive therapeutic option with less adverse effects. CENPK is known to be a subunit of the CENPH-I complex, and essential for proper kinetochore assembly (39) , but little is known about the roles of CENPK in human cancer growth, progression, and carcinogenesis. We also confirmed that CENPK is upregulated in clinical samples and TNBC cell lines, and that siRNA-mediated knockdown also causes cell growth inhibition through G0/G1 cell cycle arrest due to a loss of correct tubulin structures (Figs. 3-5) . Interestingly, we determined that other centromere or kinetochore-associated proteins, CENPA, CENPF, CENPI, CENPM, NDC80 and HJURP, were also significantly overexpressed in TNBC cases, but not expressed in normal vital organs ( Fig. 1C and Table Ⅳ) . Human CENPA was first identified based on autoantibodies found in patients suffering from scleroderma (44) and is overexpressed in colorectal cancers (45) . CENPF is also reportedly upregulated in head and neck squamous cell carcinomas and pancreatic ductal carcinomas (46, 47) . NDC80 and HJURP are reportedly overexpressed in breast cancers and associated with tumor grade and poor prognosis (48, 49) . These findings suggest that aberrant regulation of kinetochore assembly and centromere function through mitosis might contribute to the carcinogenesis of TNBC and that destroying one component of the kinetochore, such as targeting CENPK, might be a novel molecular target for TNBC treatment.
TNBC is a heterogeneous subgroup of breast cancers; therefore oncologists, pathologists, and geneticists had tried to clarify TNBC by means of gene expression profiling and immunohistochemical analyses. We also applied unsupervised 2-dimensional hierarchical clustering analysis to groups of genes based on similarities in the expression pattern, but there is no clustering for TNBC based on gene expression patterns, probably due to the small sample size (data not shown). However, the information provided in this study will facilitate the development of novel and attractive molecular drug targets without adverse events.
